Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variant

Last month, A-Alpha Bio shared their first preprint depicting how leading COVID-19 antibodies are affected by CoV-2 variants using their AlphaSeq technology. Using AlphaSeq’s large screening capabilities, 33 monoclonal antibodies tested for binding against thousands of CoV-2 variants. Over 150,000 protein-protein interactions were identified between antibodies and variants of the RBD spike protein. The implications of this paper are immediate, as many antibody prospects are in development to target the RBD spike, and unexpected mutations could cause the the virus to elude the antibody therapeutic.

Recent Posts

See All

A-Alpha Bio Secures $20M Series A Financing!

This morning we announced that we have closed a $20M Series A Financing Round to dramatically expand our capabilities and throughput! The round was led by Madrona Venture Group, our partner since the